Sensei biotherapeutics announces ind clearance by u.s. fda enabling phase 1 initiation for sns-101, a conditionally active vista-blocking antibody

First patient dose in the phase 1/2 clinical trial expected in mid-2023 first patient dose in the phase 1/2 clinical trial expected in mid-2023
SNSE Ratings Summary
SNSE Quant Ranking